On April 10, the 1st Zhengzhou International Biopharmaceutical Development Summit, a special event of the 13th China (Henan) International Investment and Trade Fair (CHIITE) was held in Zhengzhou. He Wei, vice-chairman of the National Committee of the CPPCC and executive vice-chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party, delivered a report on "The Third Era of Drug Intervention: Chinese Pharmaceutical Innovation in the Context of Cell Therapy" at the summit. He Jinping, vice-governor, Gao Tijian, vice-chairman of the Provincial Committee of the CPPCC, and over 700 representatives from nearly 300 well-known innovative pharmaceutical enterprises, venture capital firms, and universities at home and abroad attended the summit.
Henan is a province with a large population and has a huge demand for health services. It is understood that Henan's pharmaceutical industry enjoys a good foundation currently, with the overall size of the industry ranking among the tops in China, and has strong competitiveness, especially in biobreeding, biomanufacturing, biopharmacy, etc. Through the display and sharing of new achievements and experiences in biopharmaceutical research and development, this summit provides a broad platform for promoting the biopharmaceutical R&D and the development of the biopharmaceutical industry.
This summit brought together first-class talent in biopharmacy, including Chen Kaixian, an academician of the Chinese Academy of Sciences, Zhu Xun, chairman of Tongxieyi New Drug Elite Club, Li Jing, founder of Pharmacodia, and Zhang Yi, director of Biological Cytotherapy Center of the First Affiliated Hospital of Zhengzhou University, to discuss the development of new antibody drugs, as well as development and application of cell therapy and immunotherapeutic drugs in China, and to develop a vision for future development of the industry. At the same time, a book launch is held to release The Pharmaceutical Index Biologics: Monoclonal Antibody Volume I, which is a professional reference on biopharmaceuticals compiled by Chinese biopharmaceuticals insiders.
As a national hi-tech bio-industrial base, Zhengzhou Airport Economic Zone ("ZAEZ") has been actively developing bio-pharmaceutical industry in recent years. The Linkong Biopharmaceutical Park, covering an area of 2,000 mu in the southern part of ZAEZ, is committed to building a first-class biopharmaceutical industrial base integrating R&D, incubation, production and logistics in China. Currently, the base has attracted over 100 enterprises, covering innovative pharmaceutical R&D and production, research and manufacture of high-end medical devices, cell therapy and application, IVD (In vitro diagnostic) products and third-party testing. It is expected that by 2050, over 300 biomedical enterprises of various types would gather in the park, with a total output value of RMB 50 billion.
The person in charge of ZAEZ said that the Airport Experimental Zone, as the main organizer of the summit, has gained a lot, because it has not only established the image of "Biopharmaceutical Capital", but also provided the biopharmaceutical industry in ZAEZ with a booster for take-off, which would surely bring far-reaching influence to promote the development of biopharmaceutical industry in China and in Henan province, as well as the high-quality development of Zhengzhou as a national central city.